EGFR and non-small cell lung carcinoma: A randomized Phase III PAPILLON study (NCT04538664) compared amivantamab plus carboplatin‐pemetrexed versus carboplatin‐pemetrexed in patients with EGFR exon 20ins mutant NSCLC.